# Vertex Acquires Crinetics Pharmaceuticals for $10 Billion in Largest Deal in Company History

> ma · REPORTED · 2026-07-06

Vertex Pharmaceuticals agreed on July 6, 2026 to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion in equity value, in what is Vertex's largest-ever acquisition. The deal brings Crinetics' FDA-approved PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly, plus a late-stage pipeline targeting congenital adrenal hyperplasia and Cushing's syndrome.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biotech company known for its cystic fibrosis franchise that is now expanding into rare endocrine and other diseases through pipeline development and acquisitions; Crinetics Pharmaceuticals is a rare endocrine disease-focused pharma company commercializing PALSONIFY for acromegaly.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://www.businesswire.com/news/home/20260706876183/en/Vertex-to-Acquire-Crinetics-Pharmaceuticals

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.